IRIDEX Corporation (IRIX) is a Healthcare stock trading at $0.76 (as of 2026-08-20), with a market capitalization of $13.31M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
IRIDEX makes ophthalmic therapeutic laser systems, delivery devices, and related consumable instrumentation used to treat sight-threatening eye diseases like glaucoma and retinal conditions, and it monetizes this through sales of laser consoles and systems plus consumable/probe related offerings.
The company’s reported metrics highlight a profit model driven by laser system placement that grows an installed base, with continuing activity reflected in probe units sold, since it tracks both “Cyclo G6 Systems Added to Installed Base” and multiple probe unit sales measures.
| Retina | $0.0B |
| Glaucoma | $0.0B |
| Other | $0.0B |
Business quality (Weak): Based on the provided quarter snapshot, reported revenue is effectively near zero, segment disclosure is sparse, and profitability is mixed (gross margin given, but operating margin is negative), so trends may be hard to judge from this single data point.
| Price | $0.76 |
| Market Cap | $13.31M |
| Price / Book | 3.66 |
| Price / Sales | 0.26 |
| FCF Yield | -21.7% |
| Revenue (TTM) | $52.67M |
| Net Margin | -8.4% |
| Revenue Growth (YoY) | -7.4% |
| EPS Growth (YoY) | 16.7% |
| FCF Growth (YoY) | -130.2% |
| Altman Z-Score | -2.10 (distress) |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Medical Equipment) | 32.9 |
| Top Institutional Holder | BlackRock Fund Advisors ($3.42M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Medical Equipment |
| CEO | Patrick Mercer |
| Employees | 93 |
| Country | US |
| IPO Date | 1996-02-16 |
Data as of 2026-08-20.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.